• Delcath Systems announced first patient dosed in a global Phase 2 trial of HEPZATO for liver-dominant metastatic breast cancer.
• Randomized study compares HEPZATO plus standard of care versus standard of care alone in HER2-negative patients following prior treatment failure.
• About 90 patients planned across more than 20 sites in the US and Europe; primary endpoint is hepatic progression-free survival.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Delcath Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202607090800BIZWIRE_USPR_____20260709_BW141093) on July 09, 2026, and is solely responsible for the information contained therein.